11 results
DEF 14A
VRNA
Verona Pharma Plc
19 Mar 21
Definitive proxy
4:02pm
Barclays—2,928 Total—10,380 Management of capital The Group considers capital to be its equity reserves. At the current stage of the Group's life cycle
6-K
EX-1
VRNA
Verona Pharma Plc
29 Oct 20
Current report (foreign)
8:59am
formulations of ensifentrine provides expanded opportunities in life cycle management including new indications, formulation combinations
6-K
EX-1.1
p6eoz5pivki
19 Aug 20
Current report (foreign)
6:17am
6-K
EX-1.2
nj5z4vaqid
10 Mar 20
Current report (foreign)
9:46am
6-K
EX-1
mon56dfmrcfmv486 pu
28 Feb 19
Current report (foreign)
4:23pm
20-F
0a53z80 ojp
27 Feb 18
Annual report (foreign)
12:00am
- Prev
- 1
- Next